AC Immune SA (ACIU) said Tuesday that it will receive a second milestone payment of 24.6 million Swiss francs ($29.1 million) under its agreement with Johnson & Johnson (JNJ) subsidiary Janssen Pharmaceuticals.
The milestone payment follows the rapid rate of prescreening in a trial of JNJ-2056 to treat preclinical Alzheimer's disease, AC Immune said.
Shares of AC Immune were up about 8% in Tuesday's premarket activity.
Price: 3.5300, Change: +0.26, Percent Change: +7.95
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。